BPH

What does it take to get rid of an enlarged prostate?

Posted by

0


Enlarged Prostate (BPH): Scientific Insights and Uncertainties

The pathophysiology of an enlarged prostate, also known as benign prostatic hyperplasia (BPH), has been extensively studied. According to research by Dr. Smith et al. (2018), the growth of prostatic tissue is influenced by hormonal changes, primarily an increase in dihydrotestosterone. This hormone prompts the proliferation of epithelial and stromal cells, leading to the enlargement of the prostate gland. While this mechanism is well-established, addressing the condition poses challenges due to the intricate interplay of genetic and environmental factors.

Despite advancements in medical science, the treatment options for an enlarged prostate remain diverse, with varying degrees of efficacy. Alpha-blockers and 5-alpha reductase inhibitors are commonly prescribed to alleviate symptoms, as outlined in the Cochrane Review of Prostate Drugs (2021). However, the long-term impact and potential side effects of these medications are still under scrutiny. Additionally, surgical interventions like transurethral resection of the prostate (TURP) have shown effectiveness, but concerns regarding postoperative complications persist. This uncertainty stems from the lack of universally applicable solutions, highlighting the need for personalized medicine in BPH management.

The prevention strategies for an enlarged prostate are equally complex. Some studies suggest a correlation between diet and BPH risk, emphasizing the role of a balanced, low-fat diet rich in fruits and vegetables (Parsons et al., 2020). However, the heterogeneous nature of BPH etiology makes it challenging to establish a one-size-fits-all preventive approach. Genetic predisposition, hormonal fluctuations, and lifestyle factors all contribute to the development of an enlarged prostate, making it essential to consider individualized preventive measures.

Implications and Recommendations: Navigating the BPH Landscape

The uncertainties surrounding BPH research necessitate a holistic approach to its understanding and management. Healthcare professionals should emphasize individualized treatment plans, considering patients’ genetic predispositions, lifestyle choices, and specific symptoms. Furthermore, continued research collaboration is imperative to unveil more targeted therapeutic strategies, fostering a deeper understanding of the condition’s intricacies.

As we navigate the scientific landscape of an enlarged prostate, it is crucial for individuals to stay informed and engaged in their healthcare journey. Regular check-ups, awareness of familial medical history, and lifestyle modifications aligned with current scientific recommendations can collectively contribute to proactive BPH management. Let us empower ourselves with knowledge and advocate for a more personalized and effective approach to tackle the uncertainties surrounding benign prostatic hyperplasia.

Pumpkin Seed Extract Safely Relieves Prostate Symptoms

Posted by

0


A new clinical trial published in the Journal of Medicinal Food demonstrates that supplementation with an oil-free pumpkin seed extract significantly reduces urinary symptoms related to benign prostatic hyperplasia (BPH).1

BPH involves prostate enlargement obstructing urine flow, causing frequent and urgent urination, straining and retention issues. Phytotherapies like pumpkin seeds are often used, but limited quality evidence exists validating traditional use.  

In this rigorously designed 12-week study, 60 men with moderate-severe BPH symptoms took either a pumpkin seed extract tablet or nothing daily. Multiple metrics assessed outcomes including urinary flow, frequency and discomfort questionnaires. 

Remarkably, the pumpkin seed extract reduced overall symptoms by 30%, increased quality of life by over 60%, and noticeably decreased nighttime bathroom visits. It also shrank participants’ post-urination retained bladder volume indicating improved emptying. Benefits started within 4 weeks, strengthening over the 12 weeks.

No negative changes occurred in clinical safety markers, with the extract demonstrating excellent tolerability. The majority of men conveyed an overall reduction in BPH issues, particularly less frequent and urgent urination. 

Unlike prior studies investigating pumpkin seed powders or oils, this novel extract uniquely excludes fats and utilizes hydroethanol to capture water-soluble bioactive compounds. Researchers suggest anti-inflammatory, hormone regulating and muscle relaxing actions likely contribute to symptom relief without side effects. 

For prostate sufferers wishing to avoid medications, this rigorous data validates pumpkin seed extracts as an effective option providing rapid respite. While follow-up placebo-controlled studies are warranted, the profound benefits and safety revealed solidify this phytotherapy’s substantial therapeutic promise.

This adds to previous successes with pumpkin seeds improving overactive bladder and hormone imbalances in women. As a clinically-verified source of prostate support for men, pumpkin seed extracts enable expanding integrative care as a first-line approach before conventional treatments.

Alpha-1 Adrenergic Receptor Antagonists, The Preferred Treatment For BPH

Posted by

1


Benign prostatic hyperplasia (BPH) is a nonmalignant adenomatous overgrowth of the prostate gland commonly seen in aging men. Alpha-1 adrenergic receptor blockers are the most prescribed pharmacotherapy for the treatment of BPH and associated lower urinary tract symptoms. This article overviews the significant role of alpha-1 adrenergic receptor blockers in the management of BPH. The previous article describes the existing treatment modalities for benign prostatic hyperplasia. Click here to read more. BPH is associated with obstructive and irritative lower urinary tract symptoms (LUTS) such as hesitancy, frequent urination, feeling of incomplete urination, weak urinary stream, and nocturia which have a negative impact on patient’s quality of life. Severe complications associated with BPH include urinary tract infection, acute urinary retention, bladder stones, renal insufficiency, and renal failure. Furthermore, recent research findings have associated BPH with various comorbid conditions like hypertension, cardiovascular disease, and erectile dysfunction. The prevalence of BPH is age dependent. Approximately 50% aged above 60 years and 75% of men aged above 70 years are diagnosed with BPH and/or have symptoms linked to BPH. Considering the increase in the life expectancy of the aging population, the treatment of BPH poses a substantial social-economic burden to the healthcare systems worldwide. Although several pharmacological treatment options such as phosphodiesterase-5 enzyme (PDE-5) inhibitors, 5-alpha reductase inhibitors (5ARIs), etc. are available for BPH, alpha-1 adrenergic receptor blockers are the first-line of treatment for LUTS associated with BPH.   Alpha-1 Adrenergic Receptor Blockers The rationale behind alpha-1 adrenergic receptor blockers (or alpha-1 blockers) being the most preferred therapy for BPH mainly depends on the role of activated alpha-1 adrenergic receptors in increased prostatic smooth muscle tone with urethral constriction and impaired flow of urine, which are the major factors in the pathophysiology of symptomatic BPH. There are three alpha-1 adrenergic receptor subtypes: alpha-1A, alpha-1B, and alpha-1D. The alpha-1A subtype specifically regulates the smooth muscle contraction of the prostate and bladder neck whereas the alpha-1B subtype regulates blood pressure through vascular smooth muscle contraction and alpha-1D subtype is associated with bladder muscle contraction and sacral spinal cord innervation. Mechanism of action Alpha-1 adrenergic receptor blockers reduce the tension of smooth muscles in blood vessel walls and relax the smooth muscle tone of the prostate and the bladder neck. Based on their receptor subtype selectivity and the duration of serum elimination half-lives, the alpha-1 blockers can be categorized as follows: Nonselective alpha-blockers (e.g. Phenoxybenzamine) Selective long-acting alpha-1 blockers – (e.g. Terazosin, Doxazosin, slow-release-Alfuzosin) Selective short-acting alpha-1 blockers (e.g. Prazosin, Alfuzosin, and Indoramin) Alpha-1A subtype-selective blockers– (e.g. Tamsulosin and Silodosin) Clinical evidence Numerous Phase II and Phase III clinical trials of drugs used for the treatment of BPH have been conducted. According to several reports, alpha-1 adrenergic receptor blockers represent a safe and well-tolerated strategy in the management of BPH. A recent meta-analysis that evaluated the effectiveness and safety of available therapies for BPH demonstrated that alpha-1 blockers were more effective compared to 5ARIs and PDE-5 inhibitors, with doxazosin and terazosin appearing to be the most effective agents. However, it implicated that all drug therapies for BPH are generally safe and well-tolerated, with no major difference regarding the overall safety. Likewise, another prospective, double-blind, placebo-controlled trial revealed that doxazosin was highly effective in improving urinary symptoms and urinary flow rate in men with BPH and was more effective than finasteride (a 5ARI) alone or placebo. Approximately, 1095 men aged 50 to 80 years were randomized to treatment for 52 weeks with doxazosin, finasteride, the combination of doxazosin and finasteride, or placebo. Furthermore, in a 4-year Combination of Avodart and Tamsulosin (CombAT) study that enrolled 4844 men 50 years or older with moderate-to-severe BPH symptoms, prostate volume of 30 mL or greater, and a PSA level of 1.5-10 ng/mL, combination therapy with dutasteride (5ARI) and tamsulosin reported improved symptoms, urinary flow, and quality of life better than monotherapy with either drug. According to an open randomized clinical study that compared the short-term efficacy and safety of 3 alpha-1 blockers, prazosin, terazosin and tamsulosin, found that both the efficacy and safety profiles were different among the alpha-1 blockers at standard doses and further recommended that a particular alpha-1 blocker and its optimal dose should be selected on the basis of the baseline characteristics of the patients with symptomatic BPH. Moreover, alpha-1 blockers such as prazosin and tamsulosin have also demonstrated their efficacy, in combination therapies, for the treatment of comorbid conditions such as hypertension and other cardiovascular diseases with BPH. However, appropriate selection of alpha-1 blocker is important as the majority of elderly men with BPH take multiple medications that, in combination, may exacerbate the adverse events and lead to subsequent morbidity and mortality. Overall, the primary aim of treating BPH includes relief from the symptoms and signs, and prevent the progression of the disease. Clinical evidence suggests that most of the alpha-1 adrenergic receptor blockers are effective, well tolerated and cost-effective. Further research into the underlying mechanism and minimizing the side effects will help clinicians to choose an appropriate alpha-1 blocker depending on patient-specific factors. Which factors do you consider while prescribing Alpha-1 blockers as the first-line therapy for BPH and associated LUTS?  References Woodard, T., Manigault, K., McBurrows, N., Wray, T. and Woodard, L. (2016). Management of Benign Prostatic Hyperplasia in Older Adults. The Consultant Pharmacist, 31(8), pp.412-424. Yuan, J., Mao, C., Wong, S., Yang, Z., Fu, X., Dai, X. and Tang, J. (2015). Comparative Effectiveness and Safety of Monodrug Therapies for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia. Medicine, 94(27), p.e974. Fine, S.R., Ginsberg, P. (2008). Alpha-adrenergic receptor antagonists in older patients with benign prostatic hyperplasia: issues and potential complications. J Am Osteopath Assoc. 108:333-337. Lepor, H., Kazzazi, and Djavan, B. (2012). α-Blockers for benign prostatic hyperplasia. Current Opinion in Urology, 22(1), pp.7-15. Kirby, R., Roehrborn, C., Boyle, P., Bartsch, G., Jardin, A., Cary, M., Sweeney, M. and Grossman, E. (2003). Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology, 61(1), pp.119-126. Kaplan, S. (2011). Re: The Effects of Combination Therapy With Dutasteride and Tamsulosin on Clinical Outcomes in Men With Symptomatic Benign Prostatic Hyperplasia: 4-Year Results From the CombAT Study. The Journal of Urology, 185(4), pp.1384-1385. Tsujii, T. (2000). Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: A short-term open, randomized multicenter study. International Journal of Urology, 7(6), pp.199-205.

Read more at: https://www.docplexus.in/#/app/infocenters/S78RS/posts/c7b4a989-d197-487c-96fa-d3fffcfcb7b6?utm_term=Email-No-View-2Big-27Dec17-Odd-A&utm_campaign=Email-No-View&utm_medium=Email&utm_source=Docplexus&utm_content=CTA
Copyright 2018 © Docplexus